Inventiva, a clinical-stage biopharmaceutical company, announced preliminary financial results for the first half of 2026, reporting €166.1 million in cash and cash equivalents and €67.8 million in short-term deposits as of June 30, 2026. The company used €48.7 million in operating activities, mainly due to advancing its Phase 3 clinical trial for MASH treatment. No revenues were recorded in H1 2026, compared to €4.5 million in H1 2025. With recent equity and debt financing completed in June 2026, Inventiva expects to fund operations until the end of Q2 2027, potentially extending to early 2028 if additional financing milestones are met. The company continues to focus on developing lanifibranor, an oral therapy for metabolic dysfunction-associated steatohepatitis (MASH).
XRP price rose to $1.43, up 3.13% in 24 hours, with strong trading volume of $3.41 billion. Analysts highlight an inverse head-and-shoulders pattern forming, targeting a breakout above $1.55 that could trigger a 35% rally toward $2. Large holders hav...
Oracle's capital spending on AI infrastructure has surged, causing free cash flow to turn sharply negative and shifting funding reliance from internal cash to debt. This shift raises the cost of capital and pressures investment returns, evidenced by ...
Injective's Meridian mainnet upgrade proposal (IIP-701) passed with 99% support from INJ stakers, marking a major step for institutional adoption. The upgrade, scheduled for September 24, 2026, introduces regulated token standards on Injective's EVM,...
President Trump will host Chinese President Xi Jinping at the White House to discuss key issues including trade, tariffs, Taiwan, AI, and rare-earth exports. The talks come amid concerns that failure to extend a rare-earth export ban truce could esca...
Ethereum has regained the $2,500 price level amid a significant 28% drop in ETH held on exchanges since May 2025, reducing the liquid supply available for trading. Increased staking, now at over 35%, further removes ETH from circulation, tightening s...
